HK1157778A1 - A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor - Google Patents

A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor

Info

Publication number
HK1157778A1
HK1157778A1 HK11112323.0A HK11112323A HK1157778A1 HK 1157778 A1 HK1157778 A1 HK 1157778A1 HK 11112323 A HK11112323 A HK 11112323A HK 1157778 A1 HK1157778 A1 HK 1157778A1
Authority
HK
Hong Kong
Prior art keywords
vinylpyrrolidine
carboxylate
tert
butyl
preparation
Prior art date
Application number
HK11112323.0A
Other languages
English (en)
Inventor
Srinivisa Rao Akireddy
Balwinder Singh Bhatti
Timothy J Cuthbertson
Craig Harrison Miller
Jr Joseph Pike Mitchener
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of HK1157778A1 publication Critical patent/HK1157778A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
HK11112323.0A 2008-12-01 2011-11-15 A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor HK1157778A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11888508P 2008-12-01 2008-12-01
PCT/US2009/066083 WO2010065447A2 (en) 2008-12-01 2009-11-30 Novel compounds

Publications (1)

Publication Number Publication Date
HK1157778A1 true HK1157778A1 (en) 2012-07-06

Family

ID=41549744

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112323.0A HK1157778A1 (en) 2008-12-01 2011-11-15 A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor

Country Status (28)

Country Link
US (3) US8633227B2 (es)
EP (3) EP2358705A1 (es)
JP (2) JP5615836B2 (es)
KR (2) KR20110094100A (es)
CN (2) CN102232072B (es)
AR (1) AR074239A1 (es)
AU (2) AU2009322628A1 (es)
BR (2) BRPI0922630A2 (es)
CA (2) CA2744191A1 (es)
CL (2) CL2009002146A1 (es)
CO (1) CO6382158A2 (es)
EA (1) EA021054B1 (es)
EC (1) ECSP11011135A (es)
ES (1) ES2403022T3 (es)
HK (1) HK1157778A1 (es)
IL (2) IL212796A0 (es)
MX (2) MX2011005713A (es)
MY (1) MY159040A (es)
NZ (1) NZ593058A (es)
PE (1) PE20100467A1 (es)
RU (1) RU2507197C2 (es)
SA (1) SA109300715B1 (es)
SG (2) SG171432A1 (es)
TW (1) TW201024283A (es)
UA (1) UA106217C2 (es)
UY (1) UY32278A (es)
WO (2) WO2010065449A1 (es)
ZA (1) ZA201103497B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266097B (en) * 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2013116371A1 (en) * 2012-01-30 2013-08-08 Roar Biomedical Inc. Ex vivo plasma enzyme activity assay using inhibitors as a negative control
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US20160262372A1 (en) * 2015-03-13 2016-09-15 Cornell Kunz Extermination Treatment Appliance And Method
KR102485299B1 (ko) 2016-04-07 2023-01-06 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
JP3745433B2 (ja) * 1995-02-02 2006-02-15 第一製薬株式会社 複素環式化合物
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP3152438B2 (ja) * 1996-09-13 2001-04-03 シェーリング コーポレイション Ｇタンパク質機能の阻害および増殖性疾患の処置に有用な三環式化合物
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
JPH1171345A (ja) * 1997-08-30 1999-03-16 Nippon Nohyaku Co Ltd 光学活性なピロリジン誘導体及びその中間体並びにそれらの製造法
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
US6846835B2 (en) * 2000-07-11 2005-01-25 Banyu Pharmaceutical Co., Ltd. Ester derivatives
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2007054777A1 (en) * 2005-11-09 2007-05-18 Orchid Chemicals & Pharmaceuticals Limited Depletion of isomer in cephalosporin antibiotic
CN101490052B (zh) 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途

Also Published As

Publication number Publication date
EP2358670B1 (en) 2012-10-24
NZ593058A (en) 2013-06-28
MX2011005712A (es) 2011-06-17
JP2012510472A (ja) 2012-05-10
AU2009322630A1 (en) 2010-06-10
IL212799A0 (en) 2011-07-31
JP5698673B2 (ja) 2015-04-08
US20140107163A1 (en) 2014-04-17
PE20100467A1 (es) 2010-08-03
CN102232072A (zh) 2011-11-02
ECSP11011135A (es) 2011-07-29
EA201170736A1 (ru) 2011-12-30
EP2896619A1 (en) 2015-07-22
UY32278A (es) 2011-06-30
AR074239A1 (es) 2010-12-29
CA2744191A1 (en) 2010-06-10
AU2009322628A1 (en) 2010-06-10
US8633227B2 (en) 2014-01-21
CN102227406A (zh) 2011-10-26
SG171432A1 (en) 2011-07-28
JP5615836B2 (ja) 2014-10-29
RU2507197C2 (ru) 2014-02-20
IL212799A (en) 2013-12-31
CN102227406B (zh) 2013-07-31
MY159040A (en) 2016-12-15
EP2358705A1 (en) 2011-08-24
CL2009002146A1 (es) 2010-04-30
WO2010065447A3 (en) 2010-07-22
SA109300715B1 (ar) 2014-06-25
US8153821B2 (en) 2012-04-10
KR20110094318A (ko) 2011-08-23
ES2403022T3 (es) 2013-05-13
MX2011005713A (es) 2011-06-17
WO2010065447A2 (en) 2010-06-10
RU2011127004A (ru) 2013-01-10
ZA201103497B (en) 2012-01-25
CA2744197A1 (en) 2010-06-10
TW201024283A (en) 2010-07-01
EP2358670A2 (en) 2011-08-24
BRPI0922152A2 (pt) 2015-08-18
WO2010065449A1 (en) 2010-06-10
EA021054B1 (ru) 2015-03-31
SG171876A1 (en) 2011-07-28
KR20110094100A (ko) 2011-08-19
CO6382158A2 (es) 2012-02-15
CN102232072B (zh) 2014-09-24
JP2012510473A (ja) 2012-05-10
US20120015983A1 (en) 2012-01-19
CL2009002145A1 (es) 2010-04-30
US20110269975A1 (en) 2011-11-03
BRPI0922630A2 (pt) 2016-01-05
UA106217C2 (en) 2014-08-11
IL212796A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
HK1205105A1 (en) A process for the preparation of the compound and synthetic intermediates thereof
IL234285B (en) A process for the preparation of boronate ester compounds and their intermediates
AP2785A (en) Process and intermediates for preparing integrase inhibitors
GB0615620D0 (en) A process for the preparation of optically active intermediates
TWI367206B (en) Process for the preparation of prostaglandin analogues and intermediates thereof
IL198117A0 (en) Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
ZA201101836B (en) Process for the preparation of rufinamide
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
EP2496553A4 (en) NEW METHOD FOR THE PRODUCTION OF PROSTAGLANDINES AND INTERMEDIATE PRODUCTS THEREOF
IL208792A0 (en) Process for the preparation of amides
HK1157778A1 (en) A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor
SI2189442T1 (sl) Postopek in intermediati za pripravo aliskirena
PL2151429T3 (pl) Nowy sposób syntezy agomelatyny
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
EG26332A (en) Process for the preparation of benzonoprons
ZA201000397B (en) Process for preparing oxazolidine-and oxazolidinone-aminodiols and related intermediates
IL183445A0 (en) Continuous process of preparing bromopicrin
GB0813347D0 (en) A set of parts
EP2285804A4 (en) METHOD FOR MANUFACTURING PALIPERIDONE INTERMEDIATES
HK1142889A1 (en) A process for the preparation of intermediates of tetracyclic compounds
IL211382A0 (en) Process for the preparation of ethanedinitrile
IL199785A0 (en) Process and intermediates for preparing arzoxifene
EG27000A (en) Process for the preparation of ibodutant (MEN15596) and related intermediates
IL210324A0 (en) A process for preparing atovaquone and associate intermediates
GB0812613D0 (en) Process for the preparation of 1-deoxyidonojirimycin